|
⚲
|
| Keyboard |
| Armistice Capital LLC
✚
|
|
|---|---|
| CRD # | 168978 |
| SEC # | 801-100464 |
| CIK # | 0001601086 |
| AUM | 4,724.7 M (2026-03-31) |
| Employees | 30 (63% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-231-4930 |
| Address | 510 Madison Ave New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Mon, 22 Jun 2026 | Citigroup's Upgrade Caps a Run of Bullish Calls on PTC Therapeutics, a Major Armistice Capital Holding — Daily Cal |
| Tue, 19 May 2026 | InMed cuts preferred option exercise price from $16.60 to $0.80 in deal with Armistice Capital — Pluang |
| Tue, 28 Apr 2026 | Jury Clears Armistice Capital, Execs Of Securities Fraud — law360.com |
| Wed, 15 Apr 2026 | Defense says Armistice Capital trades, not fraud, drove Vaxart stock sales — Daily Journal |
| Tue, 14 Apr 2026 | Armistice Capital Used COVID To Juice Vaxart Stock, Jury Told — law360.com |
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
ITEM 5 – FEES AND COMPENSATION The fee schedules for the Funds are described in detail in each of the respective Fund’s offering memorandum. As a general matter, Armistice (or an affiliate) is paid an annual asset-based fee (the “Management Fee”) and, in some cases, receives performance compensation (the “Incentive Allocation”) from the Funds. Armistice receives a quarterly management fee calculated at an annual rate ranging from 1.25% to 1.75% of each investor’s capital account (the “Management Fee”), depending on the series to which such investor is subscribed (and subject to the caveat regarding waivers or modifications noted below). The Management Fee is paid quarterly in advance, based on the value of each investor’s capital account, as of the first business day of each calendar quarter. The Management Fee is prorated for any period that is less than a full quarter and will be adjusted for contributions and withdrawals/redemptions made during the quarter. To the extent Armistice receives the Management Fee at the Master Fund level, no Management Fee is paid at the Feeder Fund level. Subject to a loss carryforward provision, at the end of each fiscal year (December 31), the General Partner, as the holder of certain allocation class shares of the Master Fund, receives at the Master Fund level an annual incentive allocation ranging from 19% to 20% of the net profits (including realized and unrealized gains and losses), if any, attributable to each investor’s capital account (the “Incentive Allocation”), depending on the series to which such investor is subscribed. When calculating the Incentive Allocation at the Master Fund level, net profits are reduced by the Management Fee, and all items of income, loss, and expenses incurred at the Feeder Fund level are taken into account. The Feeder Funds may in the future make the Incentive Allocation at the Feeder Fund level, and in such case, no Incentive Allocation will be made at the Master Fund level. In the event that an investor withdraws/redeems capital (in whole or in part) or retires at any time other than at the end of a fiscal year, the deduction of the Incentive Allocation would be made with respect to such investor as though the withdrawal/redemption was being made at the end of a fiscal year. Under a loss carryforward provision, no Incentive Allocation will be made from the capital account of a particular investor until any net loss previously allocated to the capital account of such investor has been offset by subsequent net profits. Any such loss carryforward will be subject to reduction for withdrawals/redemptions on a pro rata basis. The General Partner/Armistice has and may continue to waive or modify the Management Fee and/or Incentive Allocation for investors that are members, employees, or affiliates of the General Partner or Armistice, relatives of such persons, and for certain other investors. Armistice deducts applicable fees from each investor’s capital account. Investors do not have the ability to choose to be billed directly for fees incurred. The Funds pay the Management Fee; Fund legal, tax and regulatory compliance, filings and reporting (including, without limitation, expenses attributable to regulatory filings that are made with respect to assets of the Funds, such as Form PF, filings required to be made pursuant to Sections 13 and 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any similar non-U.S. filing obligations); fees of third-party compliance providers; administrator, audit and accounting fees and expenses (including third- party accounting services); fees and expenses of trading and portfolio management software; organizational expenses; portfolio risk monitoring and risk analysis services; portfolio valuation fees and expenses (including third-party valuation agents); fees and expenses of the establishment and ongoing operation of any Incubator Entity (as defined in Item 10); investment expenses (whether or not the related investments are consummated) such as commissions, research fees, and expenses (including research-related travel, meals, and lodging, and market data and similar services); interest on margin accounts and other indebtedness; borrowing charges on securities sold short; custodial fees; bank service fees; Fund-related insurance costs (including D&O and E&O insurance for Armistice and the General Partner and the Master Fund’s outside Directorship liability); the Master Fund’s Directors’ fees and expenses; fees and expenses of the Master Fund’s AML Officers and anti-money laundering compliance; the Feeder Funds’ pro rata share of the expenses of the Master Fund (which may include expenses of the Funds and other investment vehicles that invest in the Master Fund); and any other expenses related to the purchase, sale or transmittal of Fund assets. The Feeder Funds will indirectly bear the administrative and other expenses of the Master Fund pro rata based on their interest in the Master Fund. The Offshore Fund will also pay for its shareholder proxy voting services, its outside Directorship liability; its Board of Directors’ fees and expenses; and its fees and expenses of AML Officers and anti-money laundering compliance. It should be noted that the Funds bear the fees, expenses, and costs of any trade errors, except for any trade errors caused by Armistice’s gross negligence or willful misconduct. The Funds also pay for research with “soft” or commission dollars. Armistice has determined such research is within the safe harbor of Section 28(e) of the Exchange Act. Refer to Item 12 – Brokerage Practices for further information. Certain of Armistice’s determinations with respect to whether specific expenses should be borne by Armistice or by its Advisory Clients require subjective judgments. Armistice has a conflict of interest when making such judgments because Armistice will bear the costs of any expenses not allocated to an Advisory ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
ITEM 7 – TYPES OF CLIENTS As described in Item 4, Armistice provides discretionary investment advisory services to private investment funds. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Agios Pharmaceuticals Inc | 0.2 | ||
| Cytokinetics Inc | 0.2 | ||
| PTC Therapeutics Inc | 0.2 | ||
| Desert Gateway Inc | 0.1 | ||
| Synta Pharmaceuticals Corp | 0.1 | ||
| Health Sciences Acquisitions Corp | 0.1 | ||
| Supernus Pharmaceuticals Inc | 0.1 | ||
| Neurocrine Biosciences Inc | 0.1 | ||
| Freshpet Inc | 0.1 | ||
| Incyte Corp | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Armistice Capital Master Fund Ltd | [2013-10-03] | 704.6 M | 4,724.7 M |
| Filed 2025-09-05 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 4.7 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 4.7 |
| By Discretionary | ||
| Discretionary | 3 | 4.7 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 4.7 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 4.7 | |
| Total | 3 | 4.7 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Steven Boyd | Executive Officer | 17 | 2 | |
| Armistice Capital LLC | Executive Officer | 2 | 2 | |
| Armistice Capital GP LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001601086] | |
| 3 | [0001601086] | |
| 4 | [0001601086] | |
| SC 13D | [0001601086] | |
| SC 13G | [0001601086] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300KF4D500QMUP976 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Avalo Therapeutics Inc AVTX
Common Stock
|
2023-06-27 | Sell | 937,404 | $0.52 | 487,450 |
|
Avalo Therapeutics Inc AVTX
Common Stock
|
2023-06-26 | Sell | 2,746,138 | $0.61 | 1,675,144 |
|
Avalo Therapeutics Inc AVTX
Common Stock
|
2023-02-07 | Buy | 450,000 | ||
|
Avalo Therapeutics Inc AVTX
Warrant · derivative
|
2023-02-07 | Buy | 450,000 | ||
|
Avalo Therapeutics Inc AVTX
Common Stock
|
2023-02-03 | Small acquisition | 334 | $3.95 | 1,319 |
|
Tenax Therapeutics Inc TENX
Series B Common Stock Purchase Warrants · derivative
|
2022-05-18 | Disposed to issuer | 3,175,924 | ||
|
Tenax Therapeutics Inc TENX
Common Stock Purchase Warrants · derivative
|
2022-05-18 | Grant | 2,072,538 | ||
|
Tenax Therapeutics Inc TENX
Warrant (right to buy) · derivative
|
2022-05-18 | Grant | 4,773,269 | ||
|
Tenax Therapeutics Inc TENX
Common Stock Purchase Warrants · derivative
|
2022-05-18 | Grant | 2,360,313 | ||
|
Tenax Therapeutics Inc TENX
Series C Common Stock Purchase Warrants · derivative
|
2022-05-18 | Disposed to issuer | 4,607,692 | ||
|
Tenax Therapeutics Inc TENX
Series B Common Stock Purchase Warrants · derivative
|
2022-05-18 | Grant | 3,175,924 | ||
|
Tenax Therapeutics Inc TENX
Common Stock Purchase Warrants · derivative
|
2022-05-18 | Disposed to issuer | 2,072,538 | ||
|
Tenax Therapeutics Inc TENX
Series C Common Stock Purchase Warrants · derivative
|
2022-05-18 | Grant | 10,596,027 | ||
|
Tenax Therapeutics Inc TENX
Series C Common Stock Purchase Warrants · derivative
|
2022-05-18 | Grant | 4,607,692 | ||
|
Tenax Therapeutics Inc TENX
Common Stock Purchase Warrants · derivative
|
2022-05-18 | Disposed to issuer | 2,360,313 | ||
|
Tenax Therapeutics Inc TENX
Warrant (right to buy) · derivative
|
2022-05-18 | Disposed to issuer | 4,773,269 | ||
|
Tenax Therapeutics Inc TENX
Pre-Funded Common Stock Purchase Warrants · derivative
|
2022-05-18 | Grant | 10,596,027 | ||
|
Avalo Therapeutics Inc AVTX
Common Stock
|
2022-03-14 | Buy | 100,000 | $0.65 | 65,000 |
|
Avalo Therapeutics Inc AVTX
Common Stock
|
2022-03-11 | Buy | 100,000 | $0.69 | 69,000 |
|
Avalo Therapeutics Inc AVTX
Common Stock
|
2022-03-10 | Buy | 26,000 | $0.70 | 18,200 |
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Encompass Capital Advisors LLC
✚
|
NY | 4,835.4 M |
|
DME Capital Management LP
✚
|
NY | 4,798.9 M |
|
Covalis Capital LLP
✚
|
4,788.9 M | |
|
Covalis Gibraltar Limited
✚
|
4,760.4 M | |
|
Mesarete Capital LLP
✚
|
4,746.1 M | |
|
Acasta Partners US LLC
✚
|
FL | 4,722.4 M |
|
Yaupon Capital Management LP
✚
|
NY | 4,684.2 M |
|
Route One Investment Company LP
✚
|
CA | 4,681.7 M |
|
Clean Energy Transition LLP
✚
|
4,630.7 M | |
|
Summit Partners Public Asset Management LLC
✚
|
MA | 4,617.4 M |